Sepsis Clinical Trial
Official title:
Safety and Efficacy Assessment of NucleoCapture Selective DNA Adsorber in Humans
Verified date | December 2022 |
Source | Santersus AG |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This open non-randomized controlled single center study investigates to what extent the removal of circulating Neutrophil Extracellular Traps (NETs) from blood by NucleoCapture device has a positive effect on the treatment of patients with sepsis and sepsis-associated AKI (SA-AKI).
Status | Completed |
Enrollment | 10 |
Est. completion date | October 24, 2021 |
Est. primary completion date | October 24, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Male or female = 18 and = 75 years of age. - Meet the clinical criteria of sepsis according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)) - Written informed consent Exclusion Criteria: - A terminal state - Active bleeding or uncontrolled acute massive bleeding |
Country | Name | City | State |
---|---|---|---|
Russian Federation | North-Western Regional Scientific and Clinical Center named after L.G. Sokolov | Saint- Petersburg |
Lead Sponsor | Collaborator |
---|---|
Santersus AG |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Blood level of neutrophil extracellular traps (NETs) change over time | Change of NETs in blood over time for each patient and in average in group | from [start of treatment] through 28 days after | |
Primary | Incidence of acute kidney injury (AKI) | Incidence of acute kidney injury (AKI) in accordance with Kidney Disease Improving Global Outcomes (KDIGO) definitions for AKI | from [start of treatment] through 28 days after | |
Primary | Severity of acute kidney injury (AKI) | Severity of acute kidney injury (AKI) in accordance with KDIGO definitions for AKI | from [start of treatment] through 28 days after | |
Primary | Rate of AKI transition to the more severe stage (for patients with AKI at baseline). | Rate of worsening of acute kidney injury (AKI) in accordance with KDIGO AKI classification (Changing stages from 1 to 2, from 2 to 3). | from [start of treatment] through 28 days after | |
Primary | Serum creatinine change over time | Change of creatinine in serum over time for each patient and in average in group | from [start of treatment] through 28 days after | |
Primary | Serum urea change over time | Change of urea in serum over time for each patient and in average in group | from [start of treatment] through 28 days after | |
Primary | Urine output change | Change of urine output over time for each patient and in average in group | from [start of treatment] through 28 days after | |
Secondary | All-cause mortality | Mortality for any reasons for each patient and in average in group | from [start of treatment] through 28 days after | |
Secondary | SOFA scores change | Change in SOFA scores over time for each patient and in average in group | from [start of treatment] through 28 days after | |
Secondary | qSOFA scores change | Change in qSOFA scores over time for each patient and in average in group | from [start of treatment] through 28 days after |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |